1 1
Out of Stock

Wegovy (Semaglutide) Injection Pen 1.7 mg, 1 Ct - Novo Nordisk

Wegovy (Semaglutide) Injection Pen 1.7 mg, 1 Ct - Novo Nordisk

PKR 54,218
PKR 54,218
Out of Stock
Pack Size: 1 x 3mL pen & 4 disposable needles
Wegovy 1.7 mg is a prescription glucagon‑like peptide‑1 (GLP‑1) receptor agonist pen used as the fourth step in the standard 16‑week dose‑escalation schedule for chronic weight management. It is indicated...  Read More
Brand: Novo Nordisk
SKU: 05712249132804
Availability: In Stock
Country: Pakistan
View full details

Description

Wegovy 1.7 mg is a prescription glucagon‑like peptide‑1 (GLP‑1) receptor agonist pen used as the fourth step in the standard 16‑week dose‑escalation schedule for chronic weight management. It is indicated for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight‑related comorbidity, and to reduce cardiovascular risk in adults with established cardiovascular disease and BMI ≥27 {start of citation}1{end of citation}. The 1.7 mg dose is taken once weekly during weeks 13‑16 of treatment as the final step‑up dose before reaching the 2.4 mg maintenance dose.

  • Final Titration Dose Before Maintenance: The 1.7 mg dose (weeks 13‑16) is the fourth and final step‑up dose in the Wegovy titration schedule, preparing patients for the transition to the 2.4 mg once‑weekly maintenance dose from week 17 onward
  • Foundation for Clinically Proven Weight Loss: When followed through to the 2.4 mg maintenance dose, Wegovy produced a mean weight loss of up to 15.6% in the STEP UP trial, with the 1.7 mg dose playing a critical role in the gradual dose escalation that minimizes gastrointestinal side effects
  • Reduces Cardiovascular Risk (as part of full regimen): When continued to the 2.4 mg maintenance dose, semaglutide is proven to reduce the risk of major adverse cardiovascular events (cardiovascular death, non‑fatal heart attack, or non‑fatal stroke) by 20% in adults with established cardiovascular disease and BMI ≥27 kg/m²
  • Once‑Weekly, Flexible Dosing: Administer subcutaneously once weekly in the abdomen, thigh, or upper arm, at any time of day, with or without meals

Composition
Each prefilled pen contains 6.8 mg semaglutide in 3 mL (2.27mg/mL)

Directions for Use

  • Use as prescribed by the physician.

Legal Disclaimer

Unless expressly indicated in the product description, MyVitaminStore.pk is not the manufacturer of the products sold on our website. While we work to ensure that product information on our website is correct, manufacturers may alter their product information. Actual product packaging and materials may contain more and/or different information than shown on our website. If you have any specific product queries, please contact the manufacturer. For medicinal products, content on our website is not intended to be used to diagnose, treat, cure, or prevent any disease or health condition or to substitute advice given by medical practitioners, pharmacists or other licensed health care professionals. You should contact your health care provider immediately if you suspect that you have a medical problem. You should always read the labels, warnings and instructions provided with the product before using or consuming it and not solely rely on the information presented on our website.

Product Overview

Wegovy 1.7 mg is a prescription glucagon‑like peptide‑1 (GLP‑1) receptor agonist pen used as the fourth step in the standard 16‑week dose‑escalation schedule for chronic weight management. It is indicated for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight‑related comorbidity, and to reduce cardiovascular risk in adults with established cardiovascular disease and BMI ≥27 {start of citation}1{end of citation}. The 1.7 mg dose is taken once weekly during weeks 13‑16 of treatment as the final step‑up dose before reaching the 2.4 mg maintenance dose.

  • Final Titration Dose Before Maintenance: The 1.7 mg dose (weeks 13‑16) is the fourth and final step‑up dose in the Wegovy titration schedule, preparing patients for the transition to the 2.4 mg once‑weekly maintenance dose from week 17 onward
  • Foundation for Clinically Proven Weight Loss: When followed through to the 2.4 mg maintenance dose, Wegovy produced a mean weight loss of up to 15.6% in the STEP UP trial, with the 1.7 mg dose playing a critical role in the gradual dose escalation that minimizes gastrointestinal side effects
  • Reduces Cardiovascular Risk (as part of full regimen): When continued to the 2.4 mg maintenance dose, semaglutide is proven to reduce the risk of major adverse cardiovascular events (cardiovascular death, non‑fatal heart attack, or non‑fatal stroke) by 20% in adults with established cardiovascular disease and BMI ≥27 kg/m²
  • Once‑Weekly, Flexible Dosing: Administer subcutaneously once weekly in the abdomen, thigh, or upper arm, at any time of day, with or without meals

Composition
Each prefilled pen contains 6.8 mg semaglutide in 3 mL (2.27mg/mL)

Directions for Use

  • Use as prescribed by the physician.

Legal Disclaimer

Unless expressly indicated in the product description, MyVitaminStore.pk is not the manufacturer of the products sold on our website. While we work to ensure that product information on our website is correct, manufacturers may alter their product information. Actual product packaging and materials may contain more and/or different information than shown on our website. If you have any specific product queries, please contact the manufacturer. For medicinal products, content on our website is not intended to be used to diagnose, treat, cure, or prevent any disease or health condition or to substitute advice given by medical practitioners, pharmacists or other licensed health care professionals. You should contact your health care provider immediately if you suspect that you have a medical problem. You should always read the labels, warnings and instructions provided with the product before using or consuming it and not solely rely on the information presented on our website.

Product Overview

Wegovy 1.7 mg is a prescription glucagon‑like peptide‑1 (GLP‑1) receptor agonist pen used as the fourth step in the standard 16‑week dose‑escalation schedule for chronic weight management. It is indicated for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight‑related comorbidity, and to reduce cardiovascular risk in adults with established cardiovascular disease and BMI ≥27 {start of citation}1{end of citation}. The 1.7 mg dose is taken once weekly during weeks 13‑16 of treatment as the final step‑up dose before reaching the 2.4 mg maintenance dose.

  • Final Titration Dose Before Maintenance: The 1.7 mg dose (weeks 13‑16) is the fourth and final step‑up dose in the Wegovy titration schedule, preparing patients for the transition to the 2.4 mg once‑weekly maintenance dose from week 17 onward
  • Foundation for Clinically Proven Weight Loss: When followed through to the 2.4 mg maintenance dose, Wegovy produced a mean weight loss of up to 15.6% in the STEP UP trial, with the 1.7 mg dose playing a critical role in the gradual dose escalation that minimizes gastrointestinal side effects
  • Reduces Cardiovascular Risk (as part of full regimen): When continued to the 2.4 mg maintenance dose, semaglutide is proven to reduce the risk of major adverse cardiovascular events (cardiovascular death, non‑fatal heart attack, or non‑fatal stroke) by 20% in adults with established cardiovascular disease and BMI ≥27 kg/m²
  • Once‑Weekly, Flexible Dosing: Administer subcutaneously once weekly in the abdomen, thigh, or upper arm, at any time of day, with or without meals

Composition
Each prefilled pen contains 6.8 mg semaglutide in 3 mL (2.27mg/mL)

Directions for Use

  • Use as prescribed by the physician.

Legal Disclaimer

Unless expressly indicated in the product description, MyVitaminStore.pk is not the manufacturer of the products sold on our website. While we work to ensure that product information on our website is correct, manufacturers may alter their product information. Actual product packaging and materials may contain more and/or different information than shown on our website. If you have any specific product queries, please contact the manufacturer. For medicinal products, content on our website is not intended to be used to diagnose, treat, cure, or prevent any disease or health condition or to substitute advice given by medical practitioners, pharmacists or other licensed health care professionals. You should contact your health care provider immediately if you suspect that you have a medical problem. You should always read the labels, warnings and instructions provided with the product before using or consuming it and not solely rely on the information presented on our website.